Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

Bevacizumab vs. Ranibizumab in Preserving or Improving Vision in Patients with Wet, Age-Related Macular Degeneration: A Cost-effectiveness Review

Submit a Paper


Clinical Medicine Insights: Therapeutics 2012:4 29-38

Review

Published on 20 Feb 2012

DOI: 10.4137/CMT.S7439


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Therapeutics

Abstract

Objective: To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered.

Methods: A Markov model was developed to assess the cost effectiveness of each of the following protocols: monthly ranibizumab, monthly bevacizumab, as-needed ranibizumab and as-needed bevacizumab. Direct costs and utilities were assessed from the perspective of a third-party payer or an insurance company. Cost effectiveness was evaluated in 2011 US dollars per quality-adjusted life year (QALY).

Results: Considering the treatment costs of severe medical and ocular adverse events, the cost effectiveness of each protocol is as follows: monthly ranibizumab $63,333/QALY, ranibizumab as needed $18,571/QALY, bevacizumab monthly $2,676/QALY and bevacizumab as needed $3,333/QALY. Sensitivity analysis of the treatment costs of medical and ocular adverse events demonstrated minimal impact on relative cost-effectiveness.

Conclusion: At current prices, monthly bevacizumab is the most cost-effective anti-VEGF AMD treatment protocol. Ranibizumab is as cost effective as bevacizumab at a maximum price of $158 per dose.



Downloads

PDF  (645.89 KB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)


Sharing


What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
My experience with Libertas Academica was an extremely positive, satisfying and rewarding one.  The process was exceptionally smooth, the author interface unusually user-friendly, and the editorial team unbelievably supportive.  Overall, I thoroughly enjoyed my publishing experience with Libertas Academica and would gladly welcome the opportunity to publish with them again.  Thank you for such a painless and gratifying publication process!
Dr Amit Bhargava (Baystate Medical Center, Springfield, MA, USA)
More Testimonials

Quick Links


New article and journal news notification services
Email Alerts RSS Feeds
Facebook Google+ Twitter
Pinterest Tumblr YouTube